Jansman, Frank G.A.; Postma, Maarten J.; Brouwers, … - In: PharmacoEconomics 25 (2007) 7, pp. 537-562
. Therefore, comparative costs and cost effectiveness are important for assessing the value of new treatment regimens. The … available study results suggest that addition of irinotecan or oxaliplatin to 5-FU/folinic acid dosage regimens is cost … effective. Also, capecitabine is calculated to be cost effective when compared with 5-FU/folinic acid. For UFT, no comparative …